Summary:
Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory disease caused by inhaling harmful fumes like cigarette smoke. It is a potentially preventable and treatable disease that affects 25% of adults at the age of 40 or older.
The purpose of this study is to observe the long term cardiovascular safety and effects on COPD exacerbations of a drug called aclidinium bromide compared to a placebo, when added to regular medications for COPD.
Qualified Participants Must:
• Be 40 years of age or older
•
Be a current or former cigarette smoker
•
Have in the past year, 2 consecutive days with increased COPD symptoms
Qualified Participants May Receive:
At no cost: study drug, study supplies, study-related medical care.
Study participation does not require insurance, and there are no co-pays or deductibles. Reasonable compensation for time and travel may also be provided to eligible participants.